secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viracta Therapeutics, Inc. (—)
CIK:        0001061027
Form:       8-K
Filed at:   2024-03-20T23:59:59+00:00
Accession:  0000950170-24-034230
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viracta CFO/COO Dan Chevallard resigns; Melody Burcar appointed interim CFO
---------------------------------------------------------------------------

- Dan Chevallard resigns as CFO and COO effective March 20, 2024 to pursue other opportunities; no disagreement with company.
- Melody Burcar appointed interim principal financial officer and principal accounting officer; previously SVP of Finance.
- Burcar receives annual base salary of $340,000, target bonus of 35%, and stock option grant of 100,000 shares at $0.99/share.
- Chevallard enters consulting agreement at $375/hour for up to 8 hours/month for up to 6 months; options/RSUs continue vesting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1061027/000095017024034230/0000950170-24-034230-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1061027/000095017024034230/virx-20240315.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-034230

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer